Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation (2013 - 2026)

Amphastar Pharmaceuticals' Accumulated Depreciation history runs 14 years deep, the most recent figure standing at $313.4 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 11.93% year-over-year to $313.4 million; the TTM figure through Mar 2026 stood at $313.4 million (up 11.93% YoY), while the FY2025 annual figure was $306.3 million, up 12.77% from the prior year.
• Accumulated Depreciation was $313.4 million for Q1 2026 at Amphastar Pharmaceuticals, up from $306.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $313.4 million in Q1 2026 to a low of $203.3 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $254.3 million across 5 years, with a median of $251.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation advanced 6.6% in 2022, then grew 12.77% in 2025.
• A 5-year view of Accumulated Depreciation shows it stood at $220.0 million in 2022, then rose by 11.48% to $245.3 million in 2023, then climbed by 10.72% to $271.6 million in 2024, then gained by 12.77% to $306.3 million in 2025, then gained by 2.32% to $313.4 million in 2026.
• The last three Accumulated Depreciation figures came in at $313.4 million (Q1 2026), $306.3 million (Q4 2025), and $298.3 million (Q3 2025), per Business Quant data.